Ann: Voluntary Suspension, page-184

lol... you can't sell them! You're trapped in this "holder" room like sheep waiting to be dipped. The only way out will be through the tank with the rest of us!

I'd like you to explain what you believe the barriers will be to commercialisation.

The way I see the basic use-case working, based on my reading of the various materials made available by Resapp is as follows:

1) Patient presents with respiratory symptoms.
2) Clinician takes patient's history and enters relevant symptoms/values into ResappDx.
3) Clinician asks patient to cough all over the device (yeurgh!).
4) Clinician clicks "send".
5) ResappDx server analyses data and sends report to practitioner.
6) Practitioner treats patient.
7) Resapp invoices practitioner's organisation.

Variations are possible. It would be possible to have the patient perform steps 1-4 without a clinician, with a modicum of instruction and some basic equipment such as a thermometer.

The commercial basis here is that the ResappDx client must be registered in order for the server to process the results. Therefore it can't be used without the service being logged and paid for. An account could easily be deactivated in the event of non-payment.

The benefit to the patient is considerable and valuable:
1) Diagnosis within minutes to an accuracy similar to traditional tests, which take hours to days.
2) Reduced incidence of undiagnosed or misdiagnosed illnesses.
3) Easy monitoring of response-to-treatment to capture incorrect diagnosis by ResappDx.
4) Ability to dispense with traditional tests in most cases, at considerable time/money saving.

To me it seems that not only is commercialisation feasible, it can be done at a rate of return that would support a very much higher market capitalisation than we currently see!

What have I missed, or what have I got wrong here, that makes you think the product can't be commercialised?